Zhang et al. have found that the BC patients with high SRC kinase activity are usually correlated with lower clinical response to trastuzumab-based therapy, higher progressive disease and shorter overall survival rates than patients having low SRC activity [32, 33]. This evidence concerns the gene SRC and breast cancer.